Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.
Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.
Income today comes from partners: upfront and milestone payments, and eventually royalties, from drugmakers that license its RNAi (RNA-interference) technology for specific targets, while it develops its own cardiometabolic drugs. Spending is heavy because it also funds its own trials.
Moat: narrow (IP / patents, process know-how). A proprietary TRiM RNAi delivery platform generates a broad, partnered pipeline across many disease areas.
Headquarters: Pasadena, California, US · Founded: 1989 · Employees: 1,059
Size Arrowhead Pharmaceuticals (ARWR) is a United States Health Care company (Biotechnology) with a market value of $6.09B, the 1047th largest of 3,085 United States companies the cockpit tracks. Shares closed at $43.11 on 18 Nov 2026.
Performance Over six months the shares fell 44.1%, against -1.0% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 45.6% over the last twelve months (peer median +16.9%); the operating margin is -156.9% (peer median -11.5%).
Valuation It trades at 14.0× enterprise value to sales against a peer median of 9.8× (7th most expensive of 16).
Credit Arrowhead Pharmaceuticals has 1 bond outstanding ($700M).
Short interest Short interest is 8.2% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $451M | $451M | $829M | $3.55M | $241M |
| Revenue growth | — | -46% | +23,258% | -99% | — |
| Gross profit | $423M | $423M | $806M | -$15.0M | $228M |
| EBITDA | -$681M | -$681M | $122M | -$582M | -$193M |
| Net income | -$724M | -$724M | -$1.63M | -$599M | -$205M |
| Free cash flow | -$284M | -$284M | $157M | -$604M | -$331M |
| Capital expenditure | $12.0M | $12.0M | $22.7M | $141M | $177M |
| Total debt | $1.40B | $1.40B | $734M | $852M | $383M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | $6.09B | -44% | -46% | -157% | 14.0× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.0B | -50% | +56% | 20% | 3.9× | 0.5% |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Wave Life Sciences WVE | $546M | -55% | -35% | -321% | 2.2× | n/a |
| Silence Therapeutics PLC Sponsored ADR SLN | $1.23B | +244% | -98% | -11,920% | 2,161.6× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARWR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.8% | -0.3% | 3rd lowest of 21 |
| 6-month return | -44.1% | -1.0% | lowest of 21 |
| Distance from 52-week high | -54.9% | -32.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | -45.6% | +16.9% | lowest of 15 |
| Operating margin | -156.9% | -11.5% | 5th lowest of 16 |
| EV / Sales | 14.0× | 9.8× | 7th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
Arrowhead Pharmaceuticals has 1 bond outstanding with $700M face value.